0000000000319624

AUTHOR

Johann Pratschke

showing 11 related works from this author

Long-term outcome after living donor liver transplantation compared to donation after brain death in autoimmune liver diseases: Experience from the E…

2021

Knowledge of living donor liver transplantation (LDLT) for autoimmune liver diseases (AILDs) is scarce. This study analyzed survival in LDLT recipients registered in the European Liver Transplant Registry with autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis (PSC) and the non-autoimmune disorder alcohol-related cirrhosis. In total, 29 902 individuals enrolled between 1998 and 2017 were analyzed, including 1003 with LDLT. Survival from >90 days after LDLT for AILDs in adults was 85.5%, 74.2%, and 58.0% after 5, 10, and 15 years. Adjusted for recipient age, sex, and liver transplantation era, adult PSC patients receiving LDLT showed increased mortality compare…

AdultMalemedicine.medical_specialtyBrain DeathCirrhosisMultivariate analysis[SDV]Life Sciences [q-bio]Medizinliving donorDiseaseAutoimmune hepatitisinflammatory030230 surgeryclinical research/practiceGastroenterologyPrimary sclerosing cholangitis03 medical and health sciences0302 clinical medicinepatient survivalInternal medicinemedicinePrimary Sclerosing CholangitisLiving DonorsImmunology and AllergyRisk-FactorsHumansPharmacology (medical)RegistriesChildRetrospective StudiesTransplantationbusiness.industryLiver DiseasesHazard ratioGraft SurvivalCohort[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.disease3. Good healthDonation after brain deathLiver TransplantationTreatment Outcome030211 gastroenterology & hepatologyimmuneMorbidityLiving donor liver transplantationbusinessliver diseaseliver transplantation/hepatologyAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant SurgeonsREFERENCES
researchProduct

High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System : success or waste of organs? The Eurotransplant 15-year all-centr…

2016

Item does not contain fulltext BACKGROUND: In the Eurotransplant Kidney Allocation System (ETKAS), transplant candidates can be considered for high-urgency (HU) status in case of life-threatening inability to undergo renal replacement therapy. Data on the outcomes of HU transplantation are sparse and the benefit is controversial. METHODS: We systematically analysed data from 898 ET HU kidney transplant recipients from 61 transplant centres between 1996 and 2010 and investigated the 5-year patient and graft outcomes and differences between relevant subgroups. RESULTS: Kidney recipients with an HU status were younger (median 43 versus 55 years) and spent less time on the waiting list compared…

Graft RejectionMalemedicine.medical_treatmentMedizin030232 urology & nephrologygraft survival030230 surgery0302 clinical medicineSurveys and QuestionnairesDIALYSISYoung adultChildKidney transplantationCANDIDATESKidneyMiddle AgedPrognosis3. Good healthEuropeMulticenter Studymedicine.anatomical_structureNephrologyChild PreschoolFemaleHemodialysisAdultReoperationmedicine.medical_specialtykidneyTissue and Organ ProcurementAdolescentWaiting ListsDonor SelectionResource AllocationYoung Adult03 medical and health sciencespatient survivalInternal medicinemedicineJournal ArticleHumansComparative StudyRenal replacement therapyDialysisAgedbusiness.industryDonor selectionInfant NewbornInfantmedicine.diseaseKidney TransplantationSurgeryTransplantationhigh-urgencyPRIORITYSURVIVAL BENEFITrenalHuman medicineRenal disorders Radboud Institute for Health Sciences [Radboudumc 11]businessWAITING TIMEtransplantationNephrology, dialysis, transplantation
researchProduct

Worldwide Techniques and Outcomes in Robot-assisted Minimally Invasive Esophagectomy (RAMIE): Results From the Multicenter International Registry

2022

OBJECTIVE: This international multicenter study by the Upper GI International Robotic Association aimed to gain insight in current techniques and outcomes of RAMIE worldwide.BACKGROUND: Current evidence for RAMIE originates from single-center studies, which may not be generalizable to the international multicenter experience.METHODS: Twenty centers from Europe, Asia, North-America, and South-America participated from 2016 to 2019. Main endpoints included the surgical techniques, clinical outcomes, and early oncological results of ramie.RESULTS: A total of 856 patients undergoing transthoracic RAMIE were included. Robotic surgery was applied for both the thoracic and abdominal phase (45%), o…

medicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatmentAnastomosisBoehmeriaRamie03 medical and health sciences0302 clinical medicineRobotic Surgical ProceduresInvasive esophagectomymedicineIvor lewisHumansMinimally Invasive Surgical ProceduresRobotic surgeryRegistriesminimally invasive surgeryroboticsRAMIEbusiness.industrySurgeryTreatment OutcomeMulticenter studyAnastomotic leakage030220 oncology & carcinogenesisesophagectomy030211 gastroenterology & hepatologySurgeryLymphadenectomybusiness
researchProduct

The activating receptor NKG2D of natural killer cells promotes resistance against enterovirus-mediated inflammatory cardiomyopathy

2014

In enterovirus-induced cardiomyopathy, information regarding the detailed impact of natural killer (NK) cells on the outcome of the disease is limited. We therefore hypothesized that NK cells and certain NK cell receptors determine the different outcome of coxsackievirus B3 (CVB3) myocarditis. Here, we demonstrate in murine models that resistance to chronic CVB3 myocarditis in immunocompetent C57BL/6 mice is characterized by significantly more mature CD11b(high) NK cells, the presence of NKG2D on NK cells, and enhanced NKG2D-dependent cytotoxicity compared to CVB3-susceptible A.BY/SnJ mice. The highly protective role of NKG2D in myocarditis was further proven by in vivo neutralization of NK…

Adoptive cell transferMyocarditisNK Cell Lectin-Like Receptor Subfamily Kchemical and pharmacologic phenomenaInflammationBiologymedicine.diseaseNKG2DPathology and Forensic MedicineInterleukin 21ImmunologyInterleukin 12medicinemedicine.symptomCD8The Journal of Pathology
researchProduct

Improved perioperative management using LiMAx test in liver surgery – preliminary results from the randomized Fast-track LiveR trial

2016

Liver surgeryLiMAx testmedicine.medical_specialtyPerioperative managementbusiness.industryGastroenterologymedicineFast trackbusinessSurgeryZeitschrift für Gastroenterologie
researchProduct

Longterm Survival After Liver Transplantation for Autoimmune Hepatitis : Results From the European Liver Transplant Registry

2020

The aim of this study was to analyze longterm patient and graft survival after liver transplantation for autoimmune hepatitis (AIH-LT) from the prospective multicenter European Liver Transplant Registry. Patient and liver graft survival between 1998 and 2017 were analyzed. Patients after AIH-LT (n = 2515) were compared with patients receiving LT for primary biliary cholangitis (PBC-LT; n = 3733), primary sclerosing cholangitis (PSC-LT; n = 5155), and alcohol-related cirrhosis (AC-LT; n = 19,567). After AIH-LT, patient survival was 79.4%, 70.8%, and 60.3% and graft survival was 73.2%, 63.4%, and 50.9% after 5, 10, and 15 years of follow-up. Overall patient survival was similar to patients af…

medicine.medical_specialtyCirrhosismedicine.medical_treatmentCholangitis SclerosingMedizinAutoimmune hepatitis030230 surgeryLiver transplantationGastroenterologyPrimary sclerosing cholangitis03 medical and health sciences0302 clinical medicineInternal medicinemedicineLiving DonorsHumansProspective StudiesRegistriesTransplantationHepatologybusiness.industryLiver Cirrhosis BiliaryHazard ratioPatient survivalmedicine.diseasedigestive system diseasesLiver TransplantationHepatitis AutoimmuneIncreased risk030211 gastroenterology & hepatologySurgeryGraft survivalbusiness
researchProduct

REsect: Blinded assessment of amenability to potentially curative treatment of previously unresectable colorectal cancer liver metastases (CRC LM) af…

2017

3532 Background: Secondary resection and radiofrequency ablation (RFA) of primarily unresectable LM from CRC can prolong survival and cure some patients (pts). Effective downsizing treatments are needed but their impact on secondary amenability to surgery/RFA is difficult to evaluate objectively. The added value of SIRT is not well established. Methods: Baseline (BL) and follow-up (FU) imaging at best response for CRC pts treated with FOLFOX chemotherapy±bevacizumab (bev) (CT) vs. CT+SIRT in the phase III SIRFLOX RCT were reviewed by 3−5 expert HPB surgeons (from a panel of 15) for resectability of LM. Reviewers were blinded to each other and to all clinical information incl. time of imagi…

Cancer Researchmedicine.medical_specialtyChemotherapyRadiofrequency ablationbusiness.industryColorectal cancermedicine.medical_treatmentmedicine.diseaselaw.inventionResection03 medical and health sciences0302 clinical medicineOncologyRandomized controlled trialFOLFOXlawCurative treatment030220 oncology & carcinogenesisClinical informationmedicine030211 gastroenterology & hepatologyRadiologybusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

2016

International audience; BACKGROUND:We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC).METHODS:In a prospective-randomized open-label international trial, 525 LTx recipients with HCC initially receiving mammalian target of rapamycin inhibitor-free immunosuppression were randomized 4 to 6 weeks after transplantation into a group on mammalian target of rapamycin inhibitor-free immunosuppression (group A: 264 patients) or a group incorporating sirolimus (group B: 261). The primary endpoint was recurrence-free survival (RFS); intention-to-treat (ITT) analysis was conducted after 8 years. Overal…

MaleTime FactorsIntention to Treat Analysimedicine.medical_treatmentMedizinPROGRESSIONKaplan-Meier EstimateLiver transplantationGastroenterologyImmunosuppressive Agent0302 clinical medicineEVEROLIMUSRENAL-CELL CARCINOMARisk FactorsMedicine and Health SciencesClinical endpointAge FactorSirolimuProspective StudiesIMMUNOSUPPRESSIONTOR Serine-Threonine KinaseTOR Serine-Threonine KinasesHazard ratioLiver NeoplasmsAge FactorsImmunosuppressionMiddle AgedCANCER3. Good healthIntention to Treat AnalysisEuropeRAPAMYCIN INHIBITORSTreatment OutcomeTARGETLocalLiver Neoplasm030220 oncology & carcinogenesisCombinationDisease ProgressionSURVIVAL[SDV.IMM]Life Sciences [q-bio]/Immunology030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleImmunosuppressive Agentsmedicine.drugHumanAdultmedicine.medical_specialtyCanadaCarcinoma HepatocellularTime Factor[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/SurgeryRisk AssessmentDisease-Free Survival03 medical and health sciencesYoung AdultDrug TherapyInternal medicinemedicineHumansAdult; Age Factors; Aged; Australia; Canada; Carcinoma Hepatocellular; Disease Progression; Disease-Free Survival; Drug Therapy Combination; Europe; Female; Humans; Immunosuppressive Agents; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Prospective Studies; Risk Assessment; Risk Factors; Sirolimus; TOR Serine-Threonine Kinases; Time Factors; Treatment Outcome; Young Adult; Liver Transplantation; TransplantationRECURRENCEMETAANALYSISAgedSirolimusTransplantationEverolimusIntention-to-treat analysisbusiness.industryRisk FactorCarcinomaAustraliaHepatocellular3126 Surgery anesthesiology intensive care radiologySurgeryLiver TransplantationTransplantationProspective StudieNeoplasm RecurrenceSirolimusNeoplasm Recurrence Localbusiness
researchProduct

Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany - Limitations of th…

2010

Summary Since the introduction of model for end-stage liver disease (MELD) in 2006, post-orthotopic liver transplantation (OLT) survival in Germany has declined. The aim of this study was to evaluate risk factors and prognostic scores for outcome. All adult OLT recipients in seven German transplant centers after MELD implementation (December 2006–December 2007) were included. Recipient data were analyzed for their influence on 1-year outcome. A total of 462 patients (mean calculated MELD = 20.5, follow-up: 1 year) were transplanted for alcoholic cirrhosis (33.1%), hepatocellular carcinoma (26.6%), Hepatitis-C (17.1%), Hepatitis-B (9.5%), primary sclerosing cholangitis (5.6%) and late graft-…

AdultMaleReoperationmedicine.medical_specialtyAlcoholic liver diseaseCarcinoma HepatocellularTissue and Organ ProcurementAdolescentmedicine.medical_treatmentMedizinLiver transplantationSeverity of Illness IndexGastroenterologyPrimary sclerosing cholangitisEnd Stage Liver DiseaseLiver diseaseModel for End-Stage Liver DiseaseRisk FactorsGermanyInternal medicinemedicineHumansRisk factorIntensive care medicineAgedRetrospective StudiesHepatitisTransplantationHealth Care Rationingbusiness.industryLiver NeoplasmsOdds ratioMiddle Agedmedicine.diseaseSurvival AnalysisLiver Transplantationbody regionsTreatment OutcomeFemalebusiness
researchProduct

Reperfusion of liver graft during transplantation: techniques used in transplant centres within Eurotransplant and meta-analysis of the literature

2013

Abstract: It remains unclear which liver graft reperfusion technique leads to the best outcome following transplantation. An online survey was sent to all transplant centres (n=37) within Eurotransplant (ET) to collect information on their technique used for reperfusion of liver grafts. Furthermore, a systematic review of all literature was performed and a meta-analysis was conducted based on patients' mortality, number of retransplantations and incidence of biliary complications, depending on the technique used. Of the 28 evaluated centres, 11 (39%) reported performing simultaneous reperfusion (SIMR), 13 (46%) perform initial portal vein reperfusion (IPR), 1 (4%) performs an initial hepati…

medicine.medical_specialtyVena cavamedicine.medical_treatmentPortal veinMedizin030230 surgeryRevascularizationVenovenous bypassretrograde reperfusionlaw.invention03 medical and health sciences0302 clinical medicineHepatic ArteryRandomized controlled triallawSurveys and QuestionnairesMedicineHumansRandomized Controlled Trials as TopicTransplantationbusiness.industryPortal Veinsimultaneous reperfusion3. Good healthSurgeryLiver TransplantationTransplantationLiver graftEuropeTreatment OutcomeMeta-analysisReperfusion030211 gastroenterology & hepatologyHuman medicineliver reperfusionbusinesssequential reperfusionLiver Circulation
researchProduct

Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the ran…

2019

Background: Secondary resection of initially unresectable colorectal cancer liver metastases (CRLM) can prolong survival. The added value of selective internal radiotherapy (SIRT) to downsize lesions for resection is not known. This study evaluated the change in technical resectability of CRLM with the addition of SIRT to FOLFOX-based chemotherapy. Methods: Baseline and follow-up hepatic imaging of patients who received modified FOLFOX (mFOLFOX6: fluorouracil, leucovorin, oxaliplatin) chemotherapy with or without bevacizumab (control arm) versus mFOLFOX6 (with or without bevacizumab) plus SIRT using yttrium-90 resin microspheres (SIRT arm) in the phase III SIRFLOX trial were reviewed by thr…

Malemedicine.medical_specialtyTime FactorsHepatic resectionTreatment outcomeAntineoplastic Agents030230 surgeryMicrosphereClinical study03 medical and health sciences0302 clinical medicinemedicineHepatectomyHumansNeoplasm MetastasisChirurgieLiver imagingRetrospective Studiesbusiness.industryIndividual participant dataLiver NeoplasmsFollow up studiesPatient dataOriginal ArticlesMiddle AgedTreatment Outcome030220 oncology & carcinogenesisFamily medicineHPBLower GISurgeryOriginal ArticleFemaleRadiotherapy AdjuvantbusinessColorectal NeoplasmsTomography X-Ray Computed:Ciencias de la Salud::Oncología [Materias Investigacion]Follow-Up Studies
researchProduct